PRPO Precipio

Precipio Announces a Shareholder Call to Discuss its COVID-19 Progress and Future Plans

Precipio Announces a Shareholder Call to Discuss its COVID-19 Progress and Future Plans

Ilan Danieli, Precipio CEO, will address questions from shareholders related to company COVID-19 strategy

NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  , will be hosting a shareholder call to address questions related to the company’s COVID-19 strategy. The call will take place on Wednesday, September 9th at 5:00PM EST. Ilan Danieli, Precipio’s CEO, will address questions sent in advance. Shareholders may submit their questions up until 5PM on September 7, 2020 by email to .

The questions addressed will be related to the company’s COVID-19 initiative, and will include questions current status and plans moving forward. 

The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call by clicking and will receive a calendar invite and a direct dial-in number, bypassing the operator.

A replay of the call will be available approximately 24 hours after the call and may be accessed via the Investors page on Precipio’s website, .

About Precipio

Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit .

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers, and the company, on our business, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the company’s ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the company’s business, operations and employees and the other factors that are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as updated from time to time in the company’s Securities and Exchange Commission filings. 

The company’s forward-looking statements in this press release are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.  

Inquiries:

Ext. 523

Inquiries:

 

  Ext. 523
EN
04/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Precipio

 PRESS RELEASE

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society...

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting Joint study conducted with Memorial Sloan Kettering Cancer Center demonstrates clear, positive impacts on patient care NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company   will be presenting at ASH the findings of a joint study conducted with scientific collaborators from in New York, evaluating Precipio’s BCR::ABL1 assay. The data from a comprehensive study includes 895 patient samples and demonstrates superior performance of the assay, while showing con...

 PRESS RELEASE

Precipio Identifies Unauthorized Access to Isolated Storage; No Operat...

Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file environment. The incident was limited to its file storage server and did not impact any of Precipio’s operations, diagnostics processes, or customer services, and the company continued to provide its services unhindered. There was no impact to patient care; nor impact to the company’s operatio...

 PRESS RELEASE

Precipio Announces its Q3-2025 Financial Results

Precipio Announces its Q3-2025 Financial Results Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter NEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  , filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for the remainder of 2025. Q3-2025 Financial Results: Revenues. Q3-2025 revenues reached $6.8M, a 30% increase YoY from $5.2M in Q3-2024, and a QoQ increase of 20% from $5.7M in Q2-2025. Pathology Services Division's services revenue increased 20% f...

 PRESS RELEASE

Precipio Announces Q3-2025 Shareholder Update Call

Precipio Announces Q3-2025 Shareholder Update Call Conference Call to be held on November 17th, 2025 at 5:00 PM EST NEW HAVEN, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  , will be hosting its Q3-2025 corporate update call on November 17th, 2025 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 800.717.1738. All callers should ask for the Precipio conference call. Listeners interested in submitting questions in advance should email their questions to  and manag...

 PRESS RELEASE

Precipio Terminates Its ATM

Precipio Terminates Its ATM Management Decision Further Reinforces Commitment to Responsible Capital Management NEW HAVEN, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  , has terminated its ATM (At-The-Market) instrument with investment bank Alliance Global Partners (AGP). “Our Company is in a much stronger position today than it was when we entered into this structure. With our elimination of negative cash flow from operations, and our recent increases of our cash balance, we now have confidence that we no longer have to rely on a tool like this for c...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch